There are 1105 resources available
207P - FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: A single-arm, phase II study
Presenter: Zizhuo Wang
Session: Poster Display session
Resources:
Abstract
208P - Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo+bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)–unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria
Presenter: Tatsuya Yamashita
Session: Poster Display session
Resources:
Abstract
209P - Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A phase II trial
Presenter: Jian-Hong Zhong
Session: Poster Display session
Resources:
Abstract
210P - Atezolizumab plus bevacizumab versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma: A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display session
Resources:
Abstract
211P - Multi-center, retrospective GUIDANCE001 trial comparing TACE with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Presenter: DaLong Yang
Session: Poster Display session
Resources:
Abstract
212P - FOLFOX-based hepatic arterial infusion chemotherapy combined with sequential drug-eluting bead transarterial chemoembolization for unresectable large hepatocellular carcinoma
Presenter: Rongce Zhao
Session: Poster Display session
Resources:
Abstract
213P - Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: A prospective, multicentric cohort study
Presenter: Jia-Yong Su
Session: Poster Display session
Resources:
Abstract
214P - Updated results from phase II study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Haibin Zhang
Session: Poster Display session
Resources:
Abstract
215P - Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with portal vein tumor thrombosis (PVTT) treated with camrelizumab, apatinib plus FOLFOX chemotherapy
Presenter: Linhui Peng
Session: Poster Display session
Resources:
Abstract
216P - Long-term outcomes of a multicenter phase II trial evaluating the efficacy of preoperative lenvatinib therapy for patients with advanced hepatocellular carcinoma
Presenter: Akihiko Ichida
Session: Poster Display session
Resources:
Abstract